Summary:
The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode
Qualified Participants Must:
• Be between 18 and 75 years of age
•
Be diagnosed with Bipolar 1 or Bipolar 2
•
Be in a current major depressive episode
Qualified Participants May Receive:
Compensation for time and travel, investigational medication or placebo and any medical care or tests needed at no cost.